Correspondence 0001193125-24-012237 from CG Oncology, Inc. (CGON) (CIK 0001991792) (CGON)
CG Oncology, Inc. (CGON) (CIK 0001991792)
Date: Jan. 22, 2024 · CIK: 0001991792 · Accession: 0001193125-24-012237
AI Filing Summary & Sentiment
File numbers found in text: 333-276350
Letter
CG Oncology, Inc.
400 Spectrum Center Drive, Suite 2040
Irvine, CA 92618
January 22, 2024
VIA EDGAR
Mr. Jimmy McNamara
Office of Life Sciences
Division of Corporation Finance
U.S. Securities and Exchange Commission
100 F Street N.E.
Washington, D.C. 20549
Re: CG Oncology, Inc.
Registration Statement on Form S-1, as amended
File No. 333-276350
Ladies and Gentlemen:
Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, the undersigned, on behalf of CG Oncology, Inc. (the “Company”), respectfully requests that the effective date of the Registration Statement on Form S-1 referred to above be accelerated so that it will become effective at 4:00 P.M. Eastern Time on January 24, 2024, or as soon as practicable thereafter.
Please contact Matthew T. Bush of Latham & Watkins LLP, counsel to the Company, at (858) 523-3962, to provide notice of effectiveness, or if you have any questions or require additional information regarding this matter. Thank you for your assistance and cooperation in this matter.
Very truly yours,
CG ONCOLOGY, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP CG Oncology, Inc. 400 Spectrum Center Drive, Suite 2040 Irvine, CA 92618 January 22, 2024 VIA EDGAR Mr. Jimmy McNamara Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 Re: CG Oncology, Inc. Registration Statement on Form S-1, as amended File No. 333-276350 Ladies and Gentlemen: Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, the undersigned, on behalf of CG Oncology, Inc. (the “Company”), respectfully requests that the effective date of the Registration Statement on Form S-1 referred to above be accelerated so that it will become effective at 4:00 P.M. Eastern Time on January 24, 2024, or as soon as practicable thereafter. Please contact Matthew T. Bush of Latham & Watkins LLP, counsel to the Company, at (858) 523-3962, to provide notice of effectiveness, or if you have any questions or require additional information regarding this matter. Thank you for your assistance and cooperation in this matter. Very truly yours, CG ONCOLOGY, INC. By: /s/ Arthur Kuan Arthur Kuan Chairman and Chief Executive Officer cc: Arthur Kuan, CG Oncology, Inc. Corleen Roche, CG Oncology, Inc. Cheston J. Larson, Latham & Watkins LLP Anthony Gostanian, Latham & Watkins LLP Charles S. Kim, Cooley LLP Denny Won, Cooley LLP Kristin VanderPas, Cooley LLP Dave Peinsipp, Cooley LLP